Zacks Investment Research
16 Sept 2026, 17:46 UTC · 1h ago
Verdict
Headline takes no side. We score HALO +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Halozyme Therapeutics is projected to achieve earnings per share (EPS) growth of 110.4% this year.
Priced inanalysis of projected growth in an opinion piece
So whatThis growth rate is roughly 7.4x the industry average of 14.9%, suggesting a significant potential upward revision to FY2026 EPS estimates.
More positive than 91% of claims this week
Halozyme Therapeutics has a historical EPS growth rate of 26.6%.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inreference to historical data
So whatMaintaining a double-digit historical floor supports the valuation multiple used by growth investors for the current cycle.
More positive than 54% of claims this week
The company's asset utilization ratio (sales-to-total-assets) currently stands at 0.67.
Priced inanalysis of existing financial metrics
So whatAn S/TA of 0.67 implies that for every $1.00 in assets, the company is generating $0.67 in revenue.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company is recommended as a great growth pick with a top Zacks Rank and projected EPS growth of 110.4%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+2.3%
Price agrees with the score
$108.69 vs $106.25 close before publication (Sep 15) · not market-adjusted
HALO chart →
